KRAS and non-small cell lung carcinoma: In oncogene-addicted cancers (HER2-mutant cancer, oncogene-driven EGFR-positive, ALK-positive, or RET-positive NSCLC), current studies do not encourage the use of immune checkpoint inhibitors, with the exception of KRAS-mutated cancers [61,64–65].